glp-1 market size 2024 Receptor Agonist Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 Obesity GLP-1 Market

5-7% Study after study has shown that patients with prediabetes who lost even 5-7% of their weight prevented progression to type 2 diabetes

Retatrutide is an investigational medicinal product

Key highlights Tirzepatide is the first dual GLP-1/GIP receptor agonist that offers stronger appetite suppression, improved glycemic control, and provides significantly greater weight loss than single receptor agonists such as semaglutide, liraglutide, and dulaglutide

Most millennials grew up in the '90s and 2000s, when heroin-chic and visible collarbones were all the rage

This knowledge ensures that the dosing schedule, recommended dosage, and potential benefits align with your specific needs